Australian biotech market watch 11/11/09
Wednesday, 11 November, 2009
Amongst the biggest winners today is Biota Holdings (ASX:BTA), up 7c to $2.78, after seeing fluctuating prices over the last couple of weeks.
Pharma company, ChemGenex (ASX:CXS), gained 3c to 91c, on the back of news of the FDA granding Priority Review status to its anti-leukaemia drug, Omapro, earlier this week.
CSL (ASX:CSL) is also up, lifting 1.5% to $32.30, recovering the losses it experienced throughout October.
Falls were experienced by pSividia (ASX:PVA), which dropped 10% to $3.23 in moderate trading, and Patrys (ASX:PAB), which this morning announced the awarding of a grant to researchers collaborating on one of its anti-cancer treatments, fell 1c to 16c.
Blackmores (ASX:BKL) dropped 40c to $20.80, and ResMed (ASX:RMD), lost 5c to $5.27. Cochlear (ASX:COH) also fell by 51c to $62, down by 0.82%.
The All Ordinaries has experienced its fourth consecutive day of gains, up 19.5 points to 4,763.5 as of 4pm this afternoon, mainly on the back of property trusts.
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
